123 related articles for article (PubMed ID: 28398409)
1. [Macrocytosis of red blood cells and early arthritis positive for rheumatoid factor such as initial manifestations of a neuroendocrine gastrin-secreting gastric tumor.].
Manzo C; Natale M; Mossetti G; Piscopo A
Recenti Prog Med; 2017 Mar; 108(3):149-151. PubMed ID: 28398409
[TBL] [Abstract][Full Text] [Related]
2. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
3. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
4. Correlation between a short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours.
Murugesan SV; Steele IA; Dimaline R; Poston GJ; Shrotri M; Campbell F; Varro A; Pritchard DM
Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):474-81. PubMed ID: 23249603
[TBL] [Abstract][Full Text] [Related]
5. [Gastric neuroendocrine tumor].
Díaz-Sánchez CL; Molano Romero RA; Martínez González M; Márquez Rivera ML; Halabe-Cherem J
Rev Gastroenterol Mex; 1998; 63(2):97-100. PubMed ID: 10068736
[TBL] [Abstract][Full Text] [Related]
6. Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions.
Vanoli A; La Rosa S; Luinetti O; Klersy C; Manca R; Alvisi C; Rossi S; Trespi E; Zangrandi A; Sessa F; Capella C; Solcia E
Hum Pathol; 2013 Sep; 44(9):1827-37. PubMed ID: 23642738
[TBL] [Abstract][Full Text] [Related]
7. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
[TBL] [Abstract][Full Text] [Related]
8. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
9. Management of Gastric Neuroendocrine Tumors: A Review.
Sok C; Ajay PS; Tsagkalidis V; Kooby DA; Shah MM
Ann Surg Oncol; 2024 Mar; 31(3):1509-1518. PubMed ID: 38062290
[TBL] [Abstract][Full Text] [Related]
10. [Gastric neuroendocrine tumors. Endoscopic and surgical treatment].
Niederle MB; Niederle B
Chirurg; 2011 Jul; 82(7):574-82. PubMed ID: 21691871
[TBL] [Abstract][Full Text] [Related]
11. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
[TBL] [Abstract][Full Text] [Related]
12. Review article: the investigation and management of gastric neuroendocrine tumours.
Basuroy R; Srirajaskanthan R; Prachalias A; Quaglia A; Ramage JK
Aliment Pharmacol Ther; 2014 May; 39(10):1071-84. PubMed ID: 24628514
[TBL] [Abstract][Full Text] [Related]
13. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?
Cavalcoli F; Zilli A; Conte D; Ciafardini C; Massironi S
Scand J Gastroenterol; 2015; 50(11):1397-403. PubMed ID: 26059834
[TBL] [Abstract][Full Text] [Related]
14. Gastric Neuroendocrine Tumor and Duodenal Gastrinoma With Chronic Autoimmune Atrophic Gastritis.
Chen WC; Warner RRP; Harpaz N; Zhu H; Roayaie S; Kim MK
Pancreas; 2019 Jan; 48(1):131-134. PubMed ID: 30531243
[TBL] [Abstract][Full Text] [Related]
15. Gastric neuroendocrine tumors.
Delle Fave G; Capurso G; Annibale B; Panzuto F
Neuroendocrinology; 2004; 80 Suppl 1():16-9. PubMed ID: 15477710
[TBL] [Abstract][Full Text] [Related]
16. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
17. [Autoimmune metaplastic atrophic gastritis, G cell hyperplasia and neuroendocrine tumor of stomach].
Chen G; Huang S
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):34-5. PubMed ID: 24713247
[No Abstract] [Full Text] [Related]
18. [Oesophageal and gastric pathology: early neoplastic lesions: case n(o) 8: an endocrine tumour of the stomach].
Scoazec JY
Ann Pathol; 2011 Oct; 31(5):390-5. PubMed ID: 21982248
[No Abstract] [Full Text] [Related]
19. Gastric neuroendocrine tumour, atrophic gastritis and autoimmune haemolytic anaemia: a case report and review.
Papakonstantinou IP; Karakousis ND; Andreadis EA
Scott Med J; 2019 Nov; 64(4):154-158. PubMed ID: 31403382
[TBL] [Abstract][Full Text] [Related]
20. Management of gastric and duodenal neuroendocrine tumors.
Sato Y; Hashimoto S; Mizuno K; Takeuchi M; Terai S
World J Gastroenterol; 2016 Aug; 22(30):6817-28. PubMed ID: 27570419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
